153 related articles for article (PubMed ID: 35150441)
41. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
42. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
43. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
44. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
[TBL] [Abstract][Full Text] [Related]
45. Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer.
Yagisawa M; Sawada K; Nakamura Y; Fujii S; Yuki S; Komatsu Y; Yoshino T; Sakamoto N; Taniguchi H
Clin Colorectal Cancer; 2021 Jun; 20(2):113-120.e1. PubMed ID: 33384243
[TBL] [Abstract][Full Text] [Related]
46. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
[TBL] [Abstract][Full Text] [Related]
47. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
Bachet JB; Moreno-Lopez N; Vigano L; Marchese U; Gelli M; Raoux L; Truant S; Laurent C; Herrero A; Le Roy B; Deguelte Lardiere S; Passot G; Hautefeuille V; De La Fouchardiere C; Artru P; Ameto T; Mabrut JY; Schwarz L; Rousseau B; Lepère C; Coriat R; Brouquet A; Sa Cunha A; Benoist S
Br J Surg; 2019 Aug; 106(9):1237-1247. PubMed ID: 31183866
[TBL] [Abstract][Full Text] [Related]
48. A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status.
Yoshida H; Shimada K; Kosuge T; Hiraoka N
Virchows Arch; 2016 Apr; 468(4):431-9. PubMed ID: 26758058
[TBL] [Abstract][Full Text] [Related]
49. Mutation Status of
Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
[TBL] [Abstract][Full Text] [Related]
50. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings.
Gheni N; Westenberg D
Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S123-S128. PubMed ID: 32108644
[TBL] [Abstract][Full Text] [Related]
51. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
[TBL] [Abstract][Full Text] [Related]
52. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R
Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147
[TBL] [Abstract][Full Text] [Related]
53. Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers.
Bae JM; Wen X; Kim TS; Kwak Y; Cho NY; Lee HS; Kang GH
Cancer Res Treat; 2020 Jan; 52(1):74-84. PubMed ID: 31096734
[TBL] [Abstract][Full Text] [Related]
54. HER2 Amplification Status in Feline Mammary Carcinoma: A Tissue Microarray-Fluorescence In Situ Hydridization-Based Study.
Muscatello LV; Di Oto E; Sarli G; Monti V; Foschini MP; Benazzi C; Brunetti B
Vet Pathol; 2019 Mar; 56(2):230-238. PubMed ID: 30384816
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry.
Sato-Kuwabara Y; Neves JI; Fregnani JH; Sallum RA; Soares FA
BMC Cancer; 2009 Jan; 9():6. PubMed ID: 19128465
[TBL] [Abstract][Full Text] [Related]
56. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
Schirripa M; Bergamo F; Cremolini C; Casagrande M; Lonardi S; Aprile G; Yang D; Marmorino F; Pasquini G; Sensi E; Lupi C; De Maglio G; Borrelli N; Pizzolitto S; Fasola G; Bertorelle R; Rugge M; Fontanini G; Zagonel V; Loupakis F; Falcone A
Br J Cancer; 2015 Jun; 112(12):1921-8. PubMed ID: 25942399
[TBL] [Abstract][Full Text] [Related]
57. Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis.
Li X; Zhao H; Gu J; Zheng L
World J Surg Oncol; 2016 Feb; 14(1):38. PubMed ID: 26897036
[TBL] [Abstract][Full Text] [Related]
58. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
59. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.
Gagnière J; Dupré A; Gholami SS; Pezet D; Boerner T; Gönen M; Kingham TP; Allen PJ; Balachandran VP; De Matteo RP; Drebin JA; Yaeger R; Kemeny NE; Jarnagin WR; D'Angelica MI
Ann Surg; 2020 Jan; 271(1):147-154. PubMed ID: 29995686
[TBL] [Abstract][Full Text] [Related]
60. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance.
Sheng WQ; Huang D; Ying JM; Lu N; Wu HM; Liu YH; Liu JP; Bu H; Zhou XY; Du X
Ann Oncol; 2013 Sep; 24(9):2360-4. PubMed ID: 23788757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]